IMpower010: Adjuvant Atezolizumab Improved DFS in PD-L1 Expressing Stage II-IIIA NSCLC

Management of Breathlessness in Lung Cancer Post-Surgery: An Interview With U.S. and U.K. Nurses

Leveraging Lung Cancer Screening Scans to Detect Early Interstitial and Obstructive Lung Disease

Low-Dose CT Screening with Guidance from Biomarkers May be Beneficial for Some Patients Who Have Never Smoked

Strategies for Implementing Lung Cancer Screening Programs in Low-Middle Income Countries

Low-Dose CT Could be One-Stop Test for Early Signs of China’s ‘Big Three’ Chest Diseases

The 50-year Journey to Optimize Lung Cancer Screening Programs

Optimizing CT Performance Through Use of Tumor Phantoms

Prolonging CT Screening Intervals is Deemed Safe in Individuals with Negative Baseline Results

A National Network Provides a Window into Lung Cancer Screening Trends, Successes across the United States

Olaparib Maintenance Did Not Improve PFS, OS in Platinum-Sensitive NSCLC

CheckMate 9LA Combination Effective in Advanced NSCLC Despite PD-L1 Expression, TMB Status